Marine Demirjian, MD
Allergy · Glendale, CANPI 1669624219
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 320 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations.
Across 320 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$990
- AstraZeneca$937
- Optinose US, Inc.$532
- Takeda Pharmaceuticals U.S.A., Inc.$317
- plus $2K from 24 others
What the payments were for
- Food & beverage$7,36599%
- Education$891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 44 | $1,257 |
| GSK | 53 | $1,223 |
| Regeneron Healthcare Solutions, Inc. | 40 | $990 |
| AstraZeneca | 41 | $937 |
| Optinose US, Inc. | 30 | $532 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $317 |
| Pfizer | 18 | $278 |
| Boehringer Ingelheim | 10 | $253 |
| Alk-abello, Inc | 8 | $236 |
| Kaleo, Inc. | 10 | $209 |
| Novartis | 7 | $151 |
| Pharming Healthcare, Inc. | 3 | $115 |
| Genentech USA, Inc. | 5 | $99 |
| Incyte Corporation | 4 | $91 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Amgen(2 entities) | 4 | $80 |
| Phadia US Inc. | 4 | $77 |
| Teva Pharmaceuticals USA, Inc. | 4 | $75 |
| Biocryst US Sales Co., LLC | 3 | $64 |
| Grifols USA, LLC | 3 | $63 |
| Hikma Pharmaceuticals USA | 3 | $54 |
| Merck | 2 | $44 |
| AbbVie | 2 | $42 |
| Octapharma USA, Inc. | 1 | $34 |
| Blueprint Medicines Corporation | 1 | $27 |
| Shire North American Group Inc | 1 | $26 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $26 |
| Organon | 1 | $22 |
| Siemens Medical Solutions USA, Inc. | 1 | $22 |
| USWM, LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,454 in reported general payments places this provider in the 70th percentile of 117 allergy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 52 | $195,577 |
| XolairOmalizumab | 59 | $136,074 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 88 | $63,403 |
| Breo ElliptaFluticasone/Vilanterol | 125 | $52,991 |
| XhanceFluticasone Propionate | 64 | $50,108 |
| Spiriva RespimatTiotropium Bromide | 39 | $21,664 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 36 | $12,457 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 99 | $9,785 |
| Azelastine Hcl | 459 | $8,928 |
| Epinephrine | 17 | $5,065 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $4,301 |
| Tacrolimus | 21 | $4,090 |
| Qvar RedihalerBeclomethasone Dipropionate | 13 | $3,591 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $3,059 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $3,048 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,223 | $116,394213 claims |
| Optinose US, Inc.Xhance | $532 | $50,10864 claims |
| Boehringer IngelheimSpiriva Respimat | $253 | $21,66439 claims |
| Hikma Pharmaceuticals USAEpinephrine | $54 | $5,06517 claims |
| AstraZenecaSymbicort | $937 | $4,30115 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $75 | $3,59113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 117 allergy providers in California.
Other allergy in Glendale
- Peter ParkerGlendale$7K
- Joshua JacobsWalnut Creek$1.5M
- Warner CarrLaguna Niguel$571K
- Bradley ChippsSacramento$571K
- Travis MillerRoseville$273K
- Robert ZeigerSan Diego$162K
- William BergerMission Viejo$76K
- Sandra ChristiansenSan Diego$74K
- Stephen WongHacienda Heights$50K
- Michelle YasharpourBeverly Hills$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.